<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02050542</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00514-41</org_study_id>
    <secondary_id>SC 3065</secondary_id>
    <nct_id>NCT02050542</nct_id>
  </id_info>
  <brief_title>Study of Current Practice Which Compare the Rate of Prostate Cancer by Using 2 Kind of Transrectal Biopsies: 3 by IRM-echography Image Fusion and 12 Systematized Guided Echographies.</brief_title>
  <acronym>MURIELLE</acronym>
  <official_title>Comparison of Prostate Cancer Detection Rates Obtained With Multiparametric MRI Targeted Transrectal Ultrasound Biopsies and Systematic Transrectal Ultrasound Biopsies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to show that 3 targeted biopsies on the suspicious image detected
      by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system, will get
      no lower rate of cancer detection than those obtained by 12 systematic transrectal
      ultrasound-guided biopsies of the prostate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The act of current practice evaluated by this research is the act of prostate biopsies : the
      patient will have to undergo 12 systematized transrectal echography guided biopsies of the
      prostate and 3 additional biopsies targeted on the suspicious lesion detected with MRI, which
      are both done in current practice.

        -  A first operator is not informed of the location of the target. He will perform a series
           of 12 systematic transrectal ultrasound-guided biopsies of the prostate.

        -  Immediately after the second operator will perform 3 additional targeted biopsies on the
           suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with
           the Koelis ® system

      Act added by the research: Using a fusion of MRI - ultrasound images software system (Koelis
      ®).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carcinomatous invasion on biopsies samples</measure>
    <time_frame>Day 15</time_frame>
    <description>The presence of carcinomatous invasion on biopsies samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue length of biopsy invaded by the detected cancer</measure>
    <time_frame>Day 15</time_frame>
    <description>Maximal tissue length of biopsy invaded by the detected cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Gleason score of the detected cancer</measure>
    <time_frame>Day 15</time_frame>
    <description>Maximal biopsy Gleason score of the detected cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respective duration of each biopsy protocol</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Targeted biopsies guided by a fusion of MRI and ultrasound</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systematic biopsies</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>systematic biopsies</intervention_name>
    <description>90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate</description>
    <arm_group_label>Targeted biopsies guided by a fusion of MRI and ultrasound</arm_group_label>
    <arm_group_label>Systematic biopsies</arm_group_label>
    <other_name>Ultrasound-guided biopsies of the prostate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted biopsies guided by a fusion of MRI and ultrasound- images</intervention_name>
    <description>Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system</description>
    <arm_group_label>Targeted biopsies guided by a fusion of MRI and ultrasound</arm_group_label>
    <arm_group_label>Systematic biopsies</arm_group_label>
    <other_name>Biopsies of the prostate by fusion of MRI and ultrasound- images with the Koelis ® system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient from 45 to 75 years old;

          -  Serum level of PSA &gt; 4,0 ng / mL;

          -  Multiparametric prostate IRM, performed before inclusion and which confirm the
             diagnosis of suspected target;

          -  No opposition of the patient notified in the medical record

          -  patient member in a national insurance scheme.

        Exclusion Criteria:

          -  Previous prostate biopsy;

          -  suspicious digital rectal examination;

          -  serum PSA &gt; 20,0 ng / mL;

          -  treatment with 5 alpha reductase inhibitor during the last 3 months;

          -  untreated urinary infection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Cornud, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitié salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>prostate</keyword>
  <keyword>PSA</keyword>
  <keyword>biopsies</keyword>
  <keyword>ultrasound</keyword>
  <keyword>MRI</keyword>
  <keyword>fusion of images</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

